Year All202420232022202120202019 Sep 18, 2023 Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer Aug 10, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results Aug 03, 2023 Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference Jun 15, 2023 Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease Jun 01, 2023 Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference May 23, 2023 Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day May 15, 2023 Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results May 09, 2023 Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference Mar 27, 2023 Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day Mar 03, 2023 Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
Sep 18, 2023 Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
Aug 10, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
Jun 15, 2023 Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
May 23, 2023 Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
May 15, 2023 Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
May 09, 2023 Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
Mar 27, 2023 Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Mar 03, 2023 Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
